topsecret09 (52.60)

Four star stock poised to pop, Lexicon Pharmaceuticals

November 24, 2009 – Comments (10) | RELATED TICKERS: LXRX

      With many key trial results being announced over the next 12 months,this biotech seems like a logical addition to anyones portfolio,with a fairly low degree of risk at this currently depressed stock price of $1.63         Key Developments   (LXRX) Lexicon completed patient enrollment ahead of schedule in a Phase 2a clinical trial of its drug candidate for non-constipating irritable bowel syndrome (IBS), LX1031, an inhibitor of tryptophan hydroxylase that acts locally in the gastrointestinal tract.  Top-line data from the trial is expected to be available in November 2009, with detailed results available in the first quarter of 2010.Lexicon completed Phase 1 studies of its drug candidate for type 2 diabetes, LX4211, an inhibitor of sodium-glucose cotransporter 2 (SGLT2).  The company also initiated a Phase 2a clinical trial of the drug candidate in patients with diabetes.  In the Phase 1 clinical trial, LX4211 was well tolerated at all dose levels and produced a dose-dependent increase in urinary glucose excretion.  LX4211 also demonstrated a favorable pharmacokinetic profile supporting the potential for once daily dosing.  The Phase 2 clinical trial is designed as a four-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX4211 and its effect on biomarkers associated with type 2 diabetes.  The trial will be conducted in the United States and is expected to enroll 36 patients with non-insulin dependent type 2 diabetes.  Top-line data from the trial is expected to be available in the first quarter of 2010.Lexicon advanced LX2931, an inhibitor of sphingosine-1-phosphate (S1P) lyase, into a Phase 2a study in patients with rheumatoid arthritis.  The Phase 2 clinical trial is designed as a 12-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX2931 and its effects on symptoms associated with rheumatoid arthritis.  The study will include up to 120 patients and will be conducted at multiple centers in the United States and Eastern Europe.  Top-line data from the trial is expected to be available in the third quarter of 2010. Lexicon continues to enroll patients in a Phase 2a study of its drug candidate for carcinoid syndrome, LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels.  The Phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome.  The study will include up to 28 patients with carcinoid syndrome who are symptomatic despite treatment with currently available therapy.  Top-line data from the trial is expected to be available by the third quarter of 2010.In October 2009, Lexicon completed the public offering and sale of 38.3 million shares of its common stock at $1.50 per share.  The net proceeds of the offering were $55.2 million, after deducting underwriting discounts and offering expenses.  http://www.lexicon-genetics.com/pipeline/index.html      Full disclosure,  Long LXRX  (14,000 shares) and adding more under $2.00  This Is not a ( FOOLISH)  Investment for longer term Investors.   TS